ProCE Banner Activity

CONRAD 138 (ENRICH): Phase I Trial of Continuous or Interrupted 90-Day TFV/LNG Vaginal Ring in Women Without HIV

Slideset Download
Conference Coverage
Both tenofovir and levonorgestrel met concentration targets in a 90-day trial assessing the TFV/LNG vaginal ring vs placebo, supporting further study of the TFV/LNG ring for HIV prevention.

Released: February 06, 2021

Expiration: February 05, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

ViiV Healthcare

Partners

IAS 2018

ProCE Banner

IAS 2021 HIV R4P

ProCE Banner